Replies to post #2 on Amylin Pharmaceuticals Inc. (AMLN)

[SeriousMoney]

Amylin May See Q3 Upside On Strong Byetta Sales
<Peter Kang, Forbes.com, 10.25.05>

Piper Jaffray maintained an "outperform" rating on Amylin Pharmaceuticals (nasdaq: AMLN - news - people ) ahead of the biotechnology company's release of third-quarter results on Wednesday.

"We continue to believe that Byetta will exceed Street expectations and upside to estimates could result in a second leg of stock appreciation near term," wrote analyst Thomas Wei in a note to investors.

http://www.forbes.com/markets/2005/10/25/amylin-pharmaceuticals-earnings-1025markets14.html?partner=...